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ABSTRACT  
   
It has been well established that mitochondria play a critical role in the 
pathology of Friedreich's Ataxia. This disease is believed to be caused by a 
deficiency of frataxin, which research suggests is responsible for iron sulfur 
cluster assembly. This incomplete assembly of iron sulfur clusters is believed to 
be linked with dysfunctional complexes in the mitochondrial respiratory chain, 
increased oxidative stress, and potential cell death. Increased understanding of the 
pathophysiology of this disease has enabled the development of various 
therapeutic strategies aimed at restoring mitochondrial respiration.  
This thesis contains an analysis of the biological activity of several classes 
of antioxidants against oxidative stress induced by diethyl maleate in Friedreich's 
Ataxia lymphocytes and CEM leukemia cells. Analogues of vitamin E α-
tocopherol have been shown to protect cells under oxidative stress. However, 
these same analogues show various levels of inhibition towards the electron 
transport chain complex I. Bicyclic pyridinols containing a ten carbon substituent 
provided favorable cytoprotection. N-hydroxy-4-pyridone compounds were 
observed to provide little protection. Similarly, analogues of CoQ10 in the form 
of pyridinol and pyrimidinol compounds also preserved cell viability at low 
concentrations. 
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INTRODUCTION 
Friedreich's Ataxia 
 
One disease associated with mitochondrial dysfunction that is of particular 
interest to our Center is Friedreich's ataxia (FRDA). FRDA is a neurodegenerative 
disorder that affects approximately 1 in 50,000 Caucasians. 
1-3
 This disease is most 
commonly seen in childhood and early teens and is characterized by a variety of 
clinical symptoms such as progressive sensory loss and corticospinal degradation. 
As the severity of the disease increases, it is normal for patients to lose the ability 
to walk. Typically, patients die prematurely from cardiomyopathy. 
4 
 
Frataxin 
 
There is a general consensus that FRDA is usually caused by a deficiency 
of frataxin, a protein that not only regulates cellular homeostasis but also mediates 
the assembly of iron-sulfur clusters (Fe-S clusters). Once produced, these Fe-S 
clusters participate in redox chemistry within the complexes of the mitochondrial 
electron transport chain.  
The deficiency of this nuclear-encoded protein is due to a GAA triplet 
expansion repeat found within the first intron of the FXN gene. 
5
 Most FRDA 
patients (95%) are homozygous for this characteristic with their alleles having 
anywhere from 70-1700 GAA triplet repeats as opposed to normal alleles having 
from 6-34 GAA repeats. 
6
 Recent work has suggested that age and onset of FRDA 
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are related to the length of the GAA triplet repeat. In addition researchers have also 
noted the presence of an inverse relationship between the amount of frataxin being 
produced and the length of the GAA triplet. To elaborate, experiments have shown 
that increasing the length of the GAA triplet resulted in lower frataxin mRNA 
levels, in vitro 
7
 and in vivo. 
8
 The presence of the GAA triplet repeat is believed to 
hinder transcription due to their ability to form DNA triplexes (DNA triple-
stranded structures). 
9
 
It is known that triplexes can be adopted by even shorter GAA repeats than 
those found in the DNA of FRDA patients. Investigation has revealed that these 
triplexes are formed at polypurine•polypyrimidine tracts via Hoogsteen base 
pairing. 
9 
Frataxin was historically believed to be a mitochondrial protein, but has 
been shown to be present in the cytosol. It is believed that frataxin participates in 
protein maturation and may contribute to the electron transport chain by interacting 
with mitochondrial aconitase to regulate energy metabolism. 
10
 Roles of frataxin 
are believed to involve multiple aspects that include Fe-S cluster assembly and the 
related processes of iron binding 
11,12 
and storage, 
13,14
 iron detoxification and 
regulation of oxidative stress. 
15-17
 Clearly, the contribution of frataxin in biological 
pathways overlaps many important domains. 
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Oxidative Phosphorylation 
 
Acting as the “powerhouse” of the cell, the mitochondria produce 
adenosine 5'-triphosphate (ATP) via oxidative phosphorylation of adenosine 
diphosphate. This produced energy is then utilized to drive many of the vital 
biochemical reactions within the cell. As the mitochondria are the site of so much 
electron trafficking, they can also be the site of significant reactive oxygen species 
(ROS) production. Much research has linked ROS to oxidative stress, aging and 
cell death. 
18,19
 Initially, the Krebs cycle provides energy in the form of electrons 
contained in the carriers nicotinamide adenine dinucleotide (NADH) and flavin 
adenine dyhydrogenase (FADH2). These are utilized by the mitochondrial 
complexes within the electron transport chain, in complex I and complex II, 
respectively. Sequentially, the electrons are passed from carriers with a low 
reduction potential to higher reduction potential. Ultimately the electrons reach 
complex IV to reduce oxygen, the final electron acceptor of the electron transport 
chain. Simultaneously, the movement of electrons down the potential gradient 
provides energy in support of translocating protons from the mitochondrial matrix 
to the intermembrane space. The generation of this proton gradient is utilized by 
ATP synthase (complex V), using the energy to condense adenosine diphosphate 
(ADP) with inorganic phosphate (Pi), thus creating ATP. In order, the respiratory 
chain protein complexes are NADH dehydrogenase-ubiquinone oxidoreductase 
(complex I), succinate dehydrogenase-ubiquinone oxidoreductase (complex II), 
ubiquinone cytochrome c oxidoreductase (complex III), cytochrome c oxidase 
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(complex IV) and ATP synthase (complex V).
1
 The transport of the electrons 
between the mitochondrial complexes involves mobile electron carriers,  including 
coenzyme Q10  and cytochrome c. 
20 
 
Superoxide Generation 
 
Under ideal conditions, all of electrons that are introduced into the 
mitochondria would be used for the reduction of oxygen to water in complex IV. 
However, this is not the fate of all electrons. Some electrons never complete the 
passage through the electron transport chain, but instead “leak” mostly from 
complexes I and III and reduce oxygen directly by one electron. 
17,20,21
 Due to the 
electronic state of oxygen, it may only accept electrons one at a time, producing a 
relatively stable intermediate, superoxide (O2
•
¯). This molecule serves as a 
precursor for a majority of ROS. 
17
 In fact, studies of mitochondria extracted from 
brain and various other organs revealed that approximately 2-5% of the total 
oxygen consumed during respiration affords ROS, mostly in the form H2O2. 
19,22-24 
It is generally believed that oxidative stress results from the imbalance of 
ROS production relative to the ability of the cell to detoxify reactive species. The 
source of the majority (~95-98%) of ROS production that occurs within the cell 
originates from the electron transport chain of the mitochondria. 
19
 As mentioned 
before, these superoxide molecules can be converted to more reactive forms of 
ROS, causing deleterious effects on biological molecules.  
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Hydroxyl Radical Formation 
 
Superoxide itself is believed not to be toxic, and actually functions in the 
regulation of biological processes. 
25
 Physiologically, superoxide can undergo a 
disproportionation reaction with itself to produce hydrogen peroxide (Equation 1). 
 
2O2
•
¯ + 2H
+
 → H2O2 + O2    (Equation 1)  
 
 This reaction occurs spontaneously. Catalysts present in the mitochondrial 
matrix such as manganese superoxide dismutases (MnSOD) can also reduce O2
•
¯ 
to H2O2. Thereafter, H2O2 can be detoxified, e.g. by catalase. Alternatively, when 
produced at high levels, H2O2 can undergo reactions that have negative 
repercussions for the cell. One reaction in particular involves the pools of Fe
2+
 
found in the mitochondrial matrix. Through Fenton chemistry, the peroxide 
produced from the dismutation of the superoxide can react with Fe
2+
. The ability of 
Fe
2+ 
to homolytically cleave the O-O bond found in H2O2 generates the highly 
toxic hydroxyl radical (HO•). 26 
 Once HO• is formed, it has the ability to react with a variety of 
macromolecules such as lipids, proteins, and DNA. 
26-29
 In particular, hydroxyl 
radical may disrupt the proton gradient responsible for ATP production by 
initiating lipid peroxidation. To elaborate, the HO• can abstract a hydrogen atom 
from a lipid membrane in order to form a carbon-center radical (R•) (Equations 2).  
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HO• + RH (lipid) → R• + H2O 
R• + O2 → ROO•     (Equations 2) 
ROO• + RH → ROOH + R• 
 
Once formed, R• can then interact with molecular oxygen to produce 
hydroperoxy radical (ROO•) at or near a diffusion-controlled rate. 30 This 
propagation proceeds with the ROO• abstracting a hydrogen atom from another 
lipid membrane, resulting in another carbon-center radical, thus repeating this 
vicious cycle. Because the mitochondria require a very dynamic and stable inner 
mitochondrial membrane, it is believed that lipid peroxidation would reduce the 
proton gradient, halting ATP production. 
17,31
 Several literature reports have 
actually suggested a role for the hydroxyl radical in the pathophysiology of FRDA 
and the damaging effects in the progression of this disease. 
32-34 
 
Mitochondrial Permeability Transition Pore 
 
Another side effect from an imbalance of ROS would be the opening of the 
mitochondrial permeability transition pore (MPTP). The MPTP has been known to 
be linked with certain avenues of cell death. 
35
 As previously mentioned, the 
mitochondrion provides the ATP needed in aerobic cells; but in addition, they 
actively participate in calcium (Ca
2+
) homeostasis. With the role of importing and 
retaining Ca
2+
, the mitochondria are able to regulate cytosolic Ca
2+
 levels; 
however, when there is an excessive amount of Ca
2+
 that exceeds the threshold 
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concentration capacity, the mitochondria respond by opening the MPTP. 
Subsequently, this opening of the MPTP results in the export of Ca
2+
 from the 
mitochondria, along with solutes that provide the support for mitochondrial 
homeostasis. With the loss of essential solutes, the mitochondrial framework and 
structure are compromised, hindering ATP production. It is hypothesized that 
oxidative stress encourages the induction of the MPTP by decreasing the Ca
2+
 
threshold concentration. 
18
 When the collapse of the electrochemical gradient 
occurs, this can lead to either caspase-mediated apoptosis or necrosis. Depending 
on the conditions, the cell can either initiate repair mechanisms or activate 
pathways resulting in cell death. 
36
 Fortunately, there exists a complicated network 
system within the mitochondria to protect cells by maintaining ROS at a basal 
level. 
 
Endogenous Defenses  
  
The presence of a wide array of enzymes to detoxify ROS and repair ROS-
induced damage are designed as defense mechanisms within a cell. As mentioned 
before, when O2
•
¯ are produced in the mitochondrial matrix, manganese 
superoxide dismutase (MnSOD) rapidly reduces O2
•
¯ to hydrogen peroxide (H2O2) 
(Equation 3).  
 
2O
-•
2 + 2H
+
 → H2O2 + O2    (Equation 3) 
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 Another important endogenous antioxidant found in the mitochondria is 
the tripeptide glutathione (L-γ-glutamyl-L-cysteinyl-glycine) (GSH) as well as 
their associated GSH-linked antioxidant enzymes (Gpx1). Having a low redox 
potential (E = -240 mV) as well as an abundance in cells (1-10 mM), glutathione is 
a major redox buffer which aids in the maintenance of cellular function. 
37
 In the 
presence of H2O2, GSH reduces H2O2 to H2O via GSH-dependent antioxidant 
enzymes. Consequently, GSH is oxidized, resulting in the formation of water from 
the 2 e
-
 transfer orchestrated by Gpx1 (Equation 4).
17 
 
H2O2 + 2GSH → GSSG + 2H2O   (Equation 4) 
 
Since superoxides are not present physiologically in the protonated form 
and are negatively charged, they are unable to cross biological membranes. 
However, it is believed that a percentage of the O2
•
¯ produced from mitochondrial 
respiration can be translocated across the intermembrane space. 
17,38
 Once in the 
intermembrane space, O2
•
¯ can undergo reduction to form H2O2 by the enzyme 
copper zinc superoxide dismutase (Cu/ZnSOD) . 
17
 In this form, H2O2 can then 
diffuse into the cytosol. 
 
Vitamin E  
 
Some cellular antioxidant defenses also include nonenzymatic strategies. 
Derived from the diet, α-tocopherol has the ability to detoxify radicals while 
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participating in recycling processes in order to reduce other vitamins. Considered 
as one of the most reactive antioxidants found in Nature, α-tocopherol works by 
donating its phenolic hydrogen to the propagating lipid peroxyl radical, with rates 
faster than the rate of chain propagation. 
39-42
 Thus, α-tocopherol is capable of 
terminating lipid peroxidation by interacting directly with peroxyl and superoxide 
radicals. Regeneration of α-tocopherol can then be achieved by interacting with 
reducing agents, in this case, ascorbic acid (vitamin C) (Scheme 1). This exchange 
of electrons continues with NADH as the final electron donor. Although it is 
believed that α-tocopherol serves as an intracellular antioxidant, it has also been 
noted to foster toxicity by exhibiting pro-oxidant properties under certain 
conditions. 
43
 
 
Coenzyme Q10 (CoQ10) 
 
As hydrophilic molecule that the human body can readily synthesize, 
CoQ10 plays a pivotal role in the electron transport chain. While it does act as an 
electron transporter, accepting electrons from complexes I and II, then transferring 
them to complex III, it can also interact with lipid hydroperoxy radicals in its 
reduced form and create superoxide (Scheme 2). Besides acting as a pro-oxidant in 
its quinone form, fully reduced CoQ10 can also act as an antioxidant by scavenging 
radicals in lipophilic regions. 
44
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Friedreich's Ataxia and Reactive Oxygen Species 
 
Despite the existence of several key antioxidants to diminish reactive 
oxygen molecules, the mitochondrion is the major source of intracellular ROS. 
This would suggest that the mitochondria may also be a susceptible to ROS 
damage, especially in settings where the mitochondria are already prone to 
excessive ROS production. 
45,46
 In FRDA, where a deficiency in frataxin is present, 
the absence of assembled Fe-S clusters within the respiratory complexes would 
impede the transport of electrons involved in mitochondrial respiration. This would 
make the electron transport chain less efficient in transporting electrons, suggesting 
that superoxide levels and other forms of ROS are likely to increase. 
17
 Therefore, 
in FRDA it is believed that ROS levels are increased as a consequence of 
dysfunctional mitochondria. This could potentially place cells under oxidative 
stress and lead to the activation of cell death signaling pathways.  
 
Treatment Outlook 
 
Figure 1 from the Friedreich’s Ataxia Research Alliance (FARA) website 
summarizes possible treatments for FRDA. The horizontal axis shows the lead 
candidates and is categorized based on approaches or mechanisms of action, while 
the vertical axis indicates the current developmental stage for each candidate. As 
shown in the bar graph, one of the primary approaches for the treatment of FRDA 
is through the use of a broad arsenal of antioxidants. This approach has seen 
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various successes in multiple cell lines and animal models of FRDA and is the 
major focus in our research. For example, high doses of CoQ10/ vitamin E in 
clinical trials have shown improvements in frataxin-deficient cardiac and skeletal 
tissue in FRDA patients over the span of the four year study. 
47
 Unfortunately, their 
poor solubility in cellular environments limits therapeutically. 
48, 49
 That is why our 
efforts have been focused towards the rational design of mitochondrial-targeted, 
multifunctional compounds aimed at quenching lipid peroxidation, scavenging 
ROS and restoring electron flow within the respiratory chain. In particular, by 
restoring electron flow, this would presumably mean replacing a missing 
component or rerouting electrons between electron carriers. With the exception of 
CoQ10 deficiency, neither CoQ10 nor synthesized analogues have been able to 
restore electron flow with respect to respiratory complex deficiency in vitro or in 
vivo. 
50
 However, very promising leads have been made using the compounds that 
contain the ubiquinone core with modifications in the number of carbon atoms on 
the side chains.  
 
The CoQ10 Analogue: Idebenone 
 
One CoQ10 analogues currently in clinical trials for the treatment of  FRDA 
is the side chain analogue, idebenone. Synthesized to undergo reversible reduction 
and oxidation reactions, idebenone exhibits antioxidant and pro-oxidant 
characteristics. It was found that idebenone can be oxidized by complex III and be 
reduced by complexes I, II, and glyceraldehyde-3-phosphate dehydrogenase. 
51
 It 
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also displays interactions with other compounds such as CoQ10 and may increase 
ROS in studies involving complex I inhibitors. 
52 
 
Bond Dissociation Enthalpy and Ionization Potential Implications 
 
Phenols have been utilized to inhibit lipid peroxidation. This is believed to 
involve the phenolic OH moiety (Equation 5).  
 
ArOH + ROO• → ArO• + ROOH           (Equation 5)     
               
This process has been described as a H atom transfer (HAT) but more 
recently has been thought to involve a more complicated mechanism called proton-
coupled electron transfer (PCET). PCET is essential for many biological energy 
conversion processes and can be used broadly to describe any mechanism 
involving the movement of both protons and electrons. In this case, a complex H-
bonding interaction occurs between the phenol and the peroxyl radical. The 
hydrogen is transferred in the form of a proton from the phenol to the lone pair of 
the peroxyl radical. Simultaneously, an electron from the 2p lone pair of the 
phenolic oxygen travels to the orbital occupied by the unpaired electron on the 
peroxyl radical. 
53
 
There is considerable effort being placed into designing antioxidants that 
possess inhibition rate constants greater than that of α-tocopherol. Unfortunately, 
limited progress has been made due to the reactivity of many compounds to O2 in 
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the atmosphere. Therefore, one of the major features that these compounds should 
display is stability to air oxidation. This describes an important parameter in 
antioxidant drug design called the ionization potential (IP), which measures the 
facility with which electrons are transferred from the phenol. Compounds having 
low IPs lose electrons and become oxidized more readily than those compounds 
having high IPs. Therefore, high IP values equate to better air stability. Another 
factor that determines antioxidant property is bond dissociation enthalpy (BDE). 
54
 
Phenols that exhibit better antioxidant efficacies generally have reduced BDEs. By 
increasing the electron density within the aromatic ring system, a lower BDE can 
be achieved, leading to stabilization of the PhO
•
. Substitution of electron-donating 
groups at the ortho and para position to the phenolic OH group tends to produce 
compounds with lower BDE. This is problematic because as the electron density 
around the ring increases to achieve a lower BDE, this also leads to a decrease in 
the IP of the phenol. 
55
 If this IP value is sufficiently low, the interaction between 
the phenol and atmospheric oxygen will occur more readily, affording ROS 
(Equation 6). 
 
ArOH + O2 → ArOH• + O2
•
¯
 
   (Equation 6) 
 
Ongoing effort has been invested into developing therapeutic strategies that 
would result in compounds that maintain air stability over an extended period of 
time while displaying sensitivity to peroxyl radicals. By introducing electron-
donating substituents at the ortho and para positions of the phenol, a reduced BDE 
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can be achieved, but with a decrease in IP as well. This decrease in IP makes the 
compound sensitive to air oxidation. This was found to be problematic in the 
synthesis of antioxidants with improved activity relative to α-tocopherol. For some 
time, only one manipulation of the chromanol ring resulted in improvement of 
antioxidant capabilities over α-tocopherol. By converting the six-membered fused 
ring to a five-membered furan, a two-fold higher kinh was observed by Ingold et al. 
53
 This was rationalized by the more favorable overlap of the lone pair from the 
heteroatom with the aromatic system. The introduction of a more electron-donating 
heteroatom, such as the case for the aza analogue of α-tocopherol, resulted in very 
fast peroxyl radical trapping abilities. However, due to a low IP, this compound 
was rendered relatively useless. In 2001, Pratt et al. presented a solution. 
56
 Their 
calculations predicted that the incorporation of nitrogen(s) into the aromatic system 
remarkably raises the IP to improve air stability of the compound, while increasing 
the BDE only slightly (Scheme 3). BDE values differed from the phenol (A) to the 
3-pyrimidinol (B) by only 1.1 kcal/mol. Additionally, differences between the 3-
pyridinol and the 5-pyrimidinol (C) was only 1.4 kcal/mol. When IP values were 
taken under consideration, by in large, there was a dramatic increase from the 
phenol to the 3-pyridinol: 11 kcal/mol. Another 13.3 kcal/mol increase in IP was 
seen when 3-pyridinol and 5-pyrimidinol were compared. 
56 
 
The presence of the electron-donating substituents in 3-pyridinols and 5-
pyrimidinols produced compounds that are very air-stable with more impressive 
radical chain-breaking abilities than α-tocopherol. This was attributed to improved 
stereoelectronic properties (Scheme 4). For example, the pyrimidinol compound 
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(A’) reacted with peroxyl radicals 2-fold faster than α-tocopherol. Even more 
impressive, the pyridinol compounds (B’, C’ and D’) were observed to have 
increased antioxidant efficacies of 5-, 28- and 88-fold relative to α-tocopherol, 
respectively. 
41
 The antioxidant properties were assessed in part by the ability of 
the compounds to suppress the oxidation of linoleic acid in benzene solution. 
 
Research Goal 
 
Oxidative stress is known to be linked to several degenerative disorders 
including cancer and aging. Understanding the implications of oxidative stress and 
developing strategies to reducing this process back to basal levels is significant to 
human health. FRDA is a condition in which this stress is believed to contribute 
towards the pathology of this disease. It is important to keep in mind that the 
oxidative stress seen in FRDA is not the underlying cause of the disease. 
Therefore, efforts to treat this oxidative stress cannot be the source of a cure. 
However, this stress does appear to contribute towards the progression of FRDA. 
So, it is our aim to develop strategies to block the oxidative stress in order to blunt 
disease progression. It is hoped that our synthesized compounds, denoted as 
multifunctional radical quenchers (MRQs), would do so by: 
1) reducing ROS production by dysfunctional mitochondria 
2) facilitating ATP production by transferring electrons between defective 
complexes 
3) protecting mitochondrial membranes and DNA from oxidative damage 
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4) conferring cytoprotection without inhibiting respiratory complexes 
We posit a mechanism for our compounds, which we believe function 
catalytically, in Scheme 5. We believe these compounds are capable of donating 
H•, to quench lipid peroxidation. This produces a resonance-stabilized 
semiquinone radical cation, which can be protonated. The latter is capable of 
oxidizing superoxide back to molecular oxygen and regenerating the starting 
compound. Therefore, the cycling between the hydroquinone and its radical cation 
by one-electron redox interactions yields a catalytic mechanism capable of 
simultaneously inhibiting lipid peroxidation and quenching superoxide anion. 
Moreover, our fully reduced compounds, if having the appropriate redox potential, 
should be capable of transferring electrons to complex III, and thereby augmenting 
ATP production. A synthetic compound capable of functioning catalytically to 
relieve dysfunctional mitochondria would be a significant milestone towards 
developing a successful therapeutic strategy for the treatment of FRDA. An 
ongoing effort in the Center for BioEnergetics (CBE) is the synthesis of 
compounds that support the requisites for MRQ function. Additionally, 
characterizations ranging from ATP production to cytoprotection assays have been 
carried out within our center for compound evaluation. Presented in this thesis are 
the cytoprotective and respiratory complex inhibition results of several classes of 
compounds designed as antioxidants, which have been designed and synthesized in 
our Center. 
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METHODS AND MATERIALS 
 
Trypan Blue Exclusion Test of Cell Viability 
FRDA lymphocytes (GM15850 cell line from Coriell Institute) and CEM-1 
leukemia cells (ATCC, catalogue number CRL-2264) were grown in 75cm
2
 flasks 
in RPMI media 1650 (Gibco, Grand Island, NY) supplemented with 15% fetal 
bovine serum (Hyclone Lab, Logan, UT) (FBS) and 10% FBS, respectively. Both 
growth medium were supplemented with 1% penicillin-streptomycin (Cell-gro, 
Manasses, VA). Cells were passaged every 2-3 days to maintain both cell lines in 
log phase and incubated at 37 °C in a humidified atmosphere containing 5% CO2 in 
air. 
For individual experiments, each cell line was seeded into sterile 24-well 
cell culture plates at a population of 500,000 cells/well. The cells were then 
incubated at 37 °C under a 5% CO2 atmosphere using several dimethyl sulfoxide 
(DMSO) dilutions (2.5 µM, 0.5 µM and 0.1 µM, or 1 µM and 5 µM) of the test 
compounds for 17 h. Oxidative stress was then induced by the use of 5 mM diethyl 
maleate (DEM) (Sigma Aldrich, St. Louis, MO). Incubation with DEM was carried 
out for 6 h for FRDA lymphocytes and 5.5 h for CEM cells, followed by 
evaluation of cytoprotection. Analysis of cell viability was carried out using trypan 
blue (membrane filtered and prepared in 0.85% saline) (Invitrogen, Carlsbad, CA) 
using an Olympus UCAMD3 inverted microscope GX41 (Japan) and a 
hematocytometer (Cole-Parmer Instruments, Vernon Hills, IL). At the time of 
measurement, the percentage of trypan blue positive cells in the DEM treated 
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control was >80%; whereas >90% of the cells were viable in the non-DEM treated 
control cells. Cytoprotection from the target compounds was then assessed with 
respect to the untreated controls, which were defined as 100%. Data are expressed 
as means ± S.E.M. (n=3). 
 
NADH Oxidase Activity Assay 
This preparation was carried out as described. 
57,58
 Initially, mitochondria 
were isolated from fresh bovine heart, which was obtained from a slaughterhouse 
and placed on ice. A temperature of 4 °C was maintained throughout all subsequent 
steps. Removal of fat and connective tissue was followed by cubing of the heart 
tissue into small pieces. Tissues were passed into a meat grinder and immersed in 
400 mL of sucrose buffer (0.25 M sucrose, 10 mM Tris-HCl, pH 7.8, containing 
0.2 mM EDTA). Cellular debris was removed via centrifugation at 1,200 × g for 20 
min to remove intact heart tissue and nuclei. Filtering through two layers of 
cheesecloth, lipid granules were removed from the supernatant. Four volumes of 
sucrose buffer were used to resuspend the mitochondrial pellet after centrifugation 
of this supernatant at 26,000 × g for 15 minutes. Homogenization proceeded using 
a tight-fitted teflon-glass Potter-Elvejhem homogenizer. The homogenate was then 
centrifuged at 12,000 × g for 30 min. The mitochondrion harvested from this pellet 
was stored at -80 °C in the same sucrose buffer. 
Submitochondrial particles (SMPs) were prepared as described. 
59
 Thawed 
mitochondria from -80 ° C storage were resuspended in sucrose buffer containing 
0.25 M sucrose, 5 mM MgCl2, 1 mM ATP, 10 mM MgCl2 and 1 mM sodium 
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succinate in 10 mM Tris-HCl, pH 7.8, and 4 °C. Sonication of this suspension was 
achieved using a sonic dismembrator (Fisher Scientific) for 30 sec each of seven 
times. To isolate large particles, the mitochondrial suspension was centrifuged at 
20,000 × g at 4 °C for 7 min. Decanting of the supernatant and centrifugation at 
152,000 × g for 25 min yielded the SMPs, which were stored at -80 °C in sucrose 
buffer (0.25 M sucrose, 5 mM MgCl2, 2 mM ATP, 2 mM glutathione, and 1 mM 
sodium succinate in 10 mM Tris-HCl, pH 7.5).  
The method used for measuring the continuous spectrophotometric rate of 
NADH oxidation in inverted SMPs (NADH oxidase activity) was described by 
Matsuno-Yagi and Hatefi. 
60
 Inhibitory effects of synthesized compounds on 
bovine heart mitochondrial complexes I, III and IV were evaluated. Serial dilutions 
(0.5 µM, 1 µM, 2.5 µM, 5 µM and 10 µM) of the test compounds were created 
using DMSO with maximal DMSO concentrations never exceeding 2% to ensure 
no influence on the enzymatic activity. Following incubation of test compounds 
with SMPs at 30 °C for 5 min in 2.5 mL of 50 mL Hepes, 5 mM MgCl2, pH 7.5, 
oxidation of 50 µM of NADH was analyzed spectrophotometrically at 340 nm (ε 
6.22 mM
-1 
cm
-1
)  using a Beckman Coulter DU-530 spectrophotometer at 30 °C. 
Initial rates were calculated with respect to the rate in absence of test compounds. 
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RESULTS 
 
The effectiveness of α-tocopherol analogues in protecting FRDA 
lymphocytes from oxidative stress was assessed (Table 1). Cells were pretreated 
with compounds 1-5 (Figure 2), which are analogues of α-tocopherol. Compounds 
1, 2, 3 and 5 contain a hydroxyl group on the third carbon of the alkyl chain at ring 
position 6. In contrast, compound 4 does not contain a hydroxyl group on this 
carbon. Measurement of cell viability revealed that compounds with the longest 
phytyl side chain provided the most protection. Specifically, α-tocopherol 
analogues having a 16-carbon side chain conferred greater cell protection than the 
analogue (1) having an 8-carbon side chain. The ability of compound 1 to protect 
cells was comparable to compounds 2-5 at 2.5 µM concentration, but its 
cytoprotective effects decreased at 0.5 and 0.1 µM concentrations. This data 
suggests that as the hydrophobicity of the side chain increases, its ability to confer 
cytoprotection tends to increase.  
Another unexpected variable was the presence of the hydroxyl group. The 
data suggests that the hydroxyl group was an important factor for effective 
cytoprotection, even more substantial than chain length per se. Compound 4, 
though containing a 16-carbon substituent afforded cell viability of just above 50% 
when used at 0.1µM concentration. However, compounds 1, 2, 3 and 5, varying in 
chain length but all having the side chain hydroxyl group, all exhibited at least 
70% cell viability at 0.1 µM concentration. 
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Further conclusions could be reached for the α-tocopherol analogues. One 
of them is in regard to stereochemistry. Compounds 3 and 5 contain the same side 
chain length but differ in their OH group stereochemistry at C3. Both compounds 
afforded approximately the same cytoprotection within experimental error, at 2.5, 
0.5, and 0.1µM concentrations. This indicates that stereochemistry at this position 
does not make a large difference in the ability to confer cytoprotection, as opposed 
to chain length or the actual presence of the hydroxyl group. 
Compounds 6-11 consisted of the bicyclic pyridinols shown in Figure 3. 
These compounds were evaluated based on the ability to confer cytoprotection to 
FRDA lymphocytes. The results are presented in Table 2. It was found that 
compounds 8 and 9 showed substantial cytoprotection, with both compounds 
affording average cell viability greater than 80% when used at concentrations of 1, 
5 and 10 µM. As indicated previously, the alkyl side chain likely aids in the 
transport of the compound to the mitochondria with current results indicating that 
C10 lipophilic side chains are a favorable length. Between compounds 8 and 9, it 
was expected that the protected compound containing the acetate might confer a 
higher average cell viability due to the increase in stability relative to the 
nonprotected compound of the same chain length. However, actual differences 
appear to not be significant. Compounds 6, 7, and 10 displayed marked increases in 
cellular protection when the test concentrations increased from 1 µM to 5 µM. The 
effects of the test compounds were the same at 5 µM and 10 µM concentrations, 
while compound 11 afforded ~ 50% cell viability at all tested concentrations. As 
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anticipated, these analogues seemed to possess cytoprotective activity, with 
activity largely dependent on chain length. 
In the study aimed at evaluating the protective defenses of N-hydroxy-4-
pyridones (Figure 4) against oxidative stress, compounds 12-18 were shown to 
have very little activity based on the results in Table 3. From Table 3, no 
compound maintained an average cell viability > 39% for FRDA lymphocytes at 
concentrations of 0.1, 0.5 and 2.5 µM. Similarly, the pyridones conferred little 
protection to CEM cells from oxidative stress (Table 4). Compound 13 exhibited 
the most cytoprotection, with cell viability averaging 34%. Attempts at modifying 
the structure of the compounds to improve cytoprotective activity are ongoing.  
Depletion of intracellular glutathione levels was accomplished by DEM 
treatment to induce oxidative stress. Following treatment, cytoprotection by 
compounds 19-23 (Figure 5) was measured using cultured FRDA lymphocytes 
(Table 5) and CEM cells (Table 6). The results indicated that compounds 21 and 
23 were the most potent cytoprotective agents. Indeed, greater potency for both 
compounds in two cell lines was seen compared to idebenone. Compound 20 also 
showed promising results at 2.5 µM concentration, but activity dropped 
significantly at 0.5 µM and 0.1 µM concentrations. Between compounds 20 and 
23, the level of cytoprotection appeared equal at 2.5 µM. However, compound 23 
exhibited stronger cytoprotection at 0.5 µM concentration compared to 
compound 20. Cell viability results from compound 22 revealed poor activity at 
all tested concentrations in both cell lines. To summarize, a few compounds (21 
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and 23) within the pyridinol and pyrimidinol class displayed impressive 
antioxidant activity, more potent than that of idebenone.  
NADH oxidase activity was measured for α-tocopherol analogues (Figure 
2) at concentrations of 10, 5, 2.5, 1 and 0.5 µM, with results presented in Table 7. 
The rate of the oxidation of NADH was quantified by the decrease in absorbance at 
340 nm. NADH oxidase activity assay revealed that α-tocopherol analogues with 
tertiary alcohols and long side chains displayed greatest affinity for the respiratory 
complexes. Concentrations of 2.5, 5, and 10 µM especially, showed moderate 
NADH oxidase inhibition, more so than the short side chain analogue 1 and the 
deoxy analogue 4. Additionally, chirality appears to not have an effect given the 
similar NADH oxidase suppression values for compounds 3 and 5. Based on these 
results, it is suggested that the long chain lengths as well as the attachment of the 
tertiary alcohol at C3 alkyl chain have important effects on the NADH oxidase 
activity. Varying results from these α-tocopherol analogues underscores the roles 
that slight differences in structure can have on the electron transport chain as a 
whole. 
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DISCUSSION 
 
Known for its fundamental role in energy metabolism, the mitochondrion 
also performs equally vital functions involving calcium homeostasis, cellular redox 
potential, and cell death signaling. Another classic characteristic of this organelle is 
that it is a key contributor of ROS production within a cell, making it a likely target 
for oxidative damage.  
FRDA cells are especially susceptible to oxidative stress due to the down-
regulation of the frataxin protein required for Fe-S cluster assembly. Lower 
frataxin levels would likely result in greater oxidative damage within the 
mitochondria due to the inefficiency of transporting electrons through complexes 
lacking essential redox mediators. Interactions between electrons that have leaked 
from the respiratory chain and molecular oxygen will produce superoxide, leading 
to oxidative stress, lipid peroxidation, and cell death. With improved understanding 
of mitochondrial dynamics, efforts have been focused on developing effective drug 
therapies. This has resulted in a myriad of compounds directed towards the 
quenching of ROS and preventing lipid peroxidation. Attempts have been made to 
synthesize novel antioxidants superior to that of the naturally occurring 
compounds. Here, vitamin E analogues and CoQ10 analogues have been evaluated 
for their cytoprotection against induced oxidative stress and NADH oxidase 
suppression. 
Protection of cultured FRDA lymphocytes was used to characterize the 
ability of the synthesized antioxidants to protect against the depletion of 
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glutathione by diethyl maleate (DEM). Upon exposure to DEM at 5 mM 
concentration, endogenous glutathione is rapidly exhausted, which results in ROS 
generation, lipid peroxidation and cell death in cultured cells. Cell viability was 
determined using the trypan blue exclusion assay. 
40
 
Assessment of novel antioxidant compounds indicate that compounds 1-5 
(Figure 2 and Table 1) were capable of significant cytoprotection of FRDA 
lymphocytes following DEM treatment. The α-tocopherol analogues containing the 
hydroxyl group on the third carbon of the C16 side chain were more effective in 
protecting cells against oxidative stress (compounds 3 and 5). Similar to the 
naturally occurring vitamin E (α-tocopherol), these analogues contain the same 
quinone ring, but differ in their lipophilic side chains. Importantly, antioxidant 
activity resides within the quinone moiety. By donating its phenolic hydrogen from 
its hydroquinone form to quench chain-propagating radicals, vitamin E and other 
quinone analogues can halt the formation of free radical chain reactions. This can 
be described as a sacrificial interaction by these antioxidants via donation of 
unpaired electrons. 
Though the importance of the tocopherol chromanol ring system is clear 
enough, without the appropriate lipophilic side chain, the radical chain breaking 
properties of these compounds may be limited. FRDA lymphocytes responded well 
to the compounds with the longer phytyl side chain, presumably reflecting 
sufficient delivery of the compounds to the site of action. By virtue of the C16 side 
chain, delivery to the mitochondrial membranes is facilitated, transporting the 
compound to the site requiring cytoprotection. In contrast, a C8 chain length might 
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not be hydrophobic enough to facilitate transport to the mitochondria. Notably, 
longer chain length may enable improved association between the phytyl side 
chain of α-tocopherol and the fatty acid residues of phospholipids in the 
mitochondrial membranes, leading to longer retention time. 
61
 Although the 
cytoporotective results suggest the length of the side chain for these α-tocopheral 
analogues is an important factor, the presence of the tertiary OH group appears to 
make more of a difference. 
The assessment of analogues possessing the pyridinol core with simple 
lipophilic side chains containing a fused five-member ring have shown 
considerable potency (Figure 3 and Table 2). By adding a second fused ring, the 
lone pair of the para-nitrogen substituent is more in conjugation to the aromatic 
system. Hence, the electron density is raised (lower bond dissociation enthalpy), 
increasing the facility with which these compounds give up a hydrogen atom to 
effectively quench the peroxyl radical. 
54
 To prevent decomposition of the 
compound in air, nitrogens were introduced in the aromatic system. The electron-
withdrawing effect of the nitrogen raises the IP (ionization potential). 
56
 Utilizing a 
simplified alkyl chain rather than a phytyl side chain that is present in α-
tocopherol, compounds modified with the favorable C9 side chain (compound 8 
and 9) appeared to retain cytoprotective activity even at the low concentration of 1 
µM. With the combination of the factors mentioned above, the bicyclic compounds 
synthesized would be likely to react very quickly to quench radicals and remain air 
stable. Within FRDA lymphocyte cell line, results demonstrated that compounds 6-
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10 were capable of protecting a majority (>70%) of cells from the effects of DEM, 
even when the compounds were used at even at 5 µM concentration. 
For this class of compounds, an approach to stabilize the bicyclic pyridinols 
by converting them to prodrugs was employed. As a widely utilized tool, the 
modification of compounds to form prodrugs was used to increase their 
pharmacological activity. 
42
 A prodrug is an inactive chemical derivative of the 
parent drug. In order to be useful, the prodrug must undergo transformation within 
the cell/body, whether by chemical or enzymatic means, to produce the active 
pharmacological agent. In fact, vitamin E (α-tocopherol) is generally administered 
as α-tocopheryl acetate to aid in the stability and solubility of the active form. 42 In 
Table 2, compound 8 carries an acetyl moiety at the C6 phenolic group, resulting in 
the temporary inactivation of its antioxidant properties. Once cleavage of the ester 
bond by esterases occurs in the cells, this yields compound 9. It is believed that 
compound 8 would afford similar cytoprotection as compound 9 due to the stability 
provided by the acetylation of its phenol moiety. Under DEM-induced oxidative 
stress, both compounds appear to afford effective and similar cytoprotection with 
cell viability averaging >80%. This could suggest that the acetate compounds are 
highly susceptible to enzymatic hydrolysis in these cells. Cleavage of the prodrug 
to produce the active parent compound within the 17 h incubation period might 
have occurred, allowing for the high cell viability obtained with compound 8 at the 
tested concentrations. Further testing at different incubation times would need to be 
carried out to observe any differences between the prodrug 8 and the active parent 
drug 9. 
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The mechanism of action for these bicyclic pyridinols is believed to be 
catalytic (Scheme 5). In keeping with the characteristics of α-tocopherol, it is 
probable that these compounds act by donating H• to a carbon-centered lipid 
radical or the hydroperoxy radical resulting from its reaction with O2. The resulting 
resonance-stabilized semiquinone radical would make this reaction relatively 
favorable. As this radical should be a strong electron acceptor, this species should 
be capable of oxidizing superoxides. This regenerates the starting compound and 
produces molecular oxygen. Therefore, it is believed that these compounds work to 
inhibit superoxides and lipid peroxidation by a catalytic quenching mechanism. 
Results collected for compounds 12-18 (Figure 4) were not significant with 
regards to cellular protection in either cell line (Table 3 and 4). It was hoped that 
these compounds would afford cytoprotection to protect cells under induced 
oxidative stress. Synthesis of compounds 12-18 was inspired based on the ROS 
scavenging capabilities of tempol.
62, 63
 Tempol is a cell membrane-permeable agent 
able to undergo one- or two-electron transfers, exhibiting antioxidant activity in 
vivo. The cellular protective property of tempol is attributed to its nitroxide moiety.  
One of the most interesting characteristics of nitroxides is their resonance 
structure in the radical form, which is made possible because of the neighboring 
elements: nitrogen and oxygen. Delocalization of the unpaired electron between 
the oxygen and nitrogen is central to the inherent stability of these compounds. 
Unfortunately, the persistence of this thermodynamically stable radical species 
relies on the unpaired electron remaining between the oxygen and nitrogen. 
However, the incorporation of the nitroxide in a six-membered ring offers an 
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enhanced gain in stabilization energy due to the spin density now being spread 
throughout the aromatic ring system. Additionally, the presence of the methyl 
group substituents adjacent to the nitrogen atom provides steric hindrance. This 
feature prevents the interaction of the nitroxide with bimolecular reactions.
63
 
Furthermore, increasing the length of the side chains is believed to facilitate 
cellular uptake of the test compounds to the lipid membranes. Taking into 
consideration the factors mentioned above in the synthesis of compounds 12-18, it 
was believed these nitroxide-containing compounds would act as strong 
cytoprotectants. Unfortunately, based on the poor cell viability observed, it is 
appears that further analyses and investigations are needed.  
Compounds 19-23 (Figure 5) represented another, interesting series of 
MRQ candidates. These compounds showed a range of potencies in protecting 
cells challenged by oxidative stress (Tables 5 and 6). Summarizing the results 
obtained from the cell viability in FRDA lymphocytes and CEM cell lines, it 
appears that compounds 21 and 23 were more effective cytoprotectants than 
idebenone. Of the compounds in this series, compound 21 was the most potent. 
This can most likely be attributed to the steric effects from the C-methyl groups 
of the pyrrolidine functional group. The presence of these methyl groups most 
likely blocks the occurrence of side reactions on the pyridine ring at the 
unsubstituted position. Additionally, the modest effects seen from compound 22 
in cytoprotection may be linked to the steric interactions when in the oxidized 
form. Attachment of the electron-donating groups in the para position of the 
phenol is believed to increase the resonance delocalization, thus stabilizing the 
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radical formed. Based on the results obtained, these compounds produced 
similar patterns in FRDA lymphocytes and CEM cells, with CEM cells 
displaying overall greater cell viability across the range of tested concentrations. 
Submitochondrial particles were isolated from bovine heart and the test 
compounds were characterized by the NADH oxidase assay (Table 7). NADH 
oxidase measures the overall transfer ability of electrons through the respiratory 
complexes I, III, and IV by monitoring the loss of NADH at 340 nm. Results 
indicated that by increasing the chain length, greater inhibition of NADH 
oxidation was seen for α-tocopherol analogues (Figure 2). In contrast, the reduced 
chain length in compound 1 led to a smaller loss of NADH oxidation. The greater 
inhibition of compound 3 and compound 5 in NADH oxidase activity may be due 
to the additional binding affinities of these compounds to either complex I, III or 
IV. Because compound 3 and 5 have been found to most strongly inhibit NADH 
oxidation, it would seem logical to suggest that this characteristic might limit their 
usefulness as antioxidants. Further studies are needed in order to determine 
exactly which complex the α-tocopherol analogues inhibit.  
Clues as to the inhibitory mechanism of these α-tocopherol analogues on 
NADH oxidation may lie in the kinetic studies aimed at probing the ubiquinone 
reduction site of complex I. Kinetic analysis experiments have suggested that 
within complex I there exists a wide, cavity-like inhibitor binding domain that can 
be occupied by varying, structurally different inhibitors, one of which includes 
idebenone.
64,65
 The manner in which this occurs can also be dissimilar, and 
structurally-dependent. The presence of a large ubiquinone binding domain agrees 
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well with data illustrating that this pocket has adequate space to house rather 
large, exogenous and perhaps inhibitory molecules.
65
 Unfortunately, the NADH 
oxidation study does not permit localization of these α-tocopherol analogues. 
Elucidation as to which specific component of the respiratory chain these 
analogues inhibit is encouraged so that further optimization strategies may 
continue. Further studies may demonstrate that these large caverns could very 
well accommodate these α-tocopherol analogues.  
  It is believed that most of these compounds provided cellular protection by 
blocking ROS production and assisted in the termination of lipid peroxidation, 
despite depletion of glutathione by DEM. Thus the possibility of cell death 
signaling pathway activation was averted, and cell viability was preserved. In 
contrast, moderate inhibition of any one of the respiratory complexes (I, III or IV) 
by several α-tocopherol analogues was revealed through the NADH oxidase assay. 
With these observations, it seems likely that further modifications of the various 
compound classes, while retaining their core, can be utilized to preserve 
mitochondrial function. This work establishes the cytoprotective capabilities of 
several classes of compounds designed to aid dysfunctional respiratory complexes. 
These and other characterization studies may provide clues into identifying the 
structural derivatives that can restore electron flow and support ATP production 
without exhibiting respiratory chain inhibition.  
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Scheme 1. Participants in the regeneration of α-tocopherol (α-TOH), from phenoxyl radical form (α-TOH•).66 
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Scheme 2: Antioxidant and pro-oxidant reactions of quinones. Here, the fully reduced quinol form possesses 
the antioxidant effect while the fully oxidized form can react with molecular oxygen to produce superoxides. 
Dehydrogenases found within the cell can reduce the quinone to give the quinol in the mitochondrial 
membrane.67 
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Scheme 3. Bond dissociation enthalpy (BDE) and ionization potential (IP) for phenol, 3-pyrimidinol and 5-
pyrimidinol.56 Values are expressed in units of kcal/mol. 
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Scheme 4. Derivatives of pyridinols with 5 (B’), 28 (C’) and 88 (D’) times more reactivity than α-tocopherol 
in trapping peroxyl radicals.41 
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Scheme 5. Catalytic function of MRQs. Quenching of lipid peroxidation by MRQs via PCET (proton-coupled 
electron transfer) generates a phenoxyl radical that can be protonated. The latter compound can react with 
superoxide to generate the starting compound and molecular oxygen.69 
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Table 1 
 
Cytoprotective effects of compounds 1-5 in FRDA lymphocytes 
 
______________________________________________________ 
 
 
Compound                                         Cell Viability (%)                    
______________________________________________________ 
 
                                           0.1 µM          0.5 µM         2.5 µM    
______________________________________________________ 
 
Untreated control
a
              97 ± 1.0         97 ± 1.0        97 ± 1.0 
 
Treated  control
b
                16 ± 3.8         16 ± 3.8        16 ± 3.8 
 
  1                                       70 ± 6.2         68 ± 1.1       86 ± 3.4         
 
  2                                       72 ± 3.6         90 ± 2.8       88 ± 1.2 
 
  3                                       77 ± 1.4         84 ± 1.3       92 ± 1.3     
 
  4                                       54 ± 6.1         62 ± 2.4       79 ± 3.5 
 
  5                                       80 ± 1.2         80 ± 3.7       91 ± 4.6 
 
______________________________________________________ 
 
Compounds containing the 2,3-dimethoxy-5-methyl-1,4-bnezoquinone core with varying nonpolar side chains 
at the 6th position on cell viability were evaluated. After incubation of test compounds with cultured FRDA 
lymphocytes, oxidative stress was induced using DEM. Percentage values in this assay were normalized to the 
untreated control. 
a
 No DEM Treatment. 
b 
DEM Treatment. 
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Table 2 
 
Cytoprotective effects of compounds 6-11in FRDA lymphocytes 
 
______________________________________________________ 
 
Compound                         Cell Viability (%) 
 
______________________________________________________ 
 
                                1 µM            5 µM          10 µM        
______________________________________________________ 
 
Untreated control
a
            97 ± 1.2       97 ± 1.2       97 ± 1.2    
 
Treated control
b
               18 ± 4.3       18 ± 4.3       18 ± 4.3 
 
6                                       33 ± 2.2       71 ± 3.1       74 ± 2.9  
 
7                                       46 ± 5.0       73 ± 2.3       73 ± 2.6   
 
8                                       86 ± 3.2       87 ± 2.0       87 ± 2.5                
 
9                                       83 ± 3.1       84 ± 4.5       84 ± 5.7 
 
10                                     26 ± 4.3       73 ± 3.5       79 ± 3.9 
 
11                                     49 ± 1.4       48 ± 4.2       49 ± 2.2 
 
______________________________________________________ 
 
Compounds of the bicyclic 6-amino-3-pyridinol variety with differing nonpolar side chains on cell viability 
were evaluated. After incubation of test compounds with cultured FRDA lymphocytes, oxidative stress was 
induced using DEM. Percentage values in this assay were normalized to the untreated control. 
a
 No DEM Treatment. 
b 
DEM Treatment. 
 
 
 
 
 
 
 
 
 
    44  
Table 3 
 
Cytoprotective effects of compounds 12-18 in FRDA lymphocytes 
 
______________________________________________________ 
 
Compound                        Cell Viability (%) 
 
______________________________________________________ 
 
                                     0.1 µM         0.5 µM       2.5 µM      
______________________________________________________ 
 
Untreated control
a
        97 ± 2.6       97 ± 2.6      97 ± 2.6 
 
Treated control
b
           17 ± 2.1        17 ± 2.1      17 ± 2.1 
 
12                                 27 ± 8.2        30 ± 3.4      24 ± 6.1 
 
13                                 31 ± 3.0        28 ± 7.5      32 ± 5.3 
 
14                                 15 ± 6.4        29 ± 3.1      39 ± 3.2 
 
15                                 36 ± 7.2        14 ± 5.7      20 ± 3.5            
 
16                                 19 ± 6.6        21 ± 3.9      32 ± 2.3 
 
17                                 17 ± 3.5        14 ± 2.8      19 ± 6.2 
 
18                                 19 ± 6.4        15 ± 5.5      18 ± 2.5 
 
______________________________________________________ 
 
Results for N-hydroxy-4-pyridone derivatives with varying side chains at the C5 position on cell viability are 
as shown. After incubation of test compounds with cultured FRDA lymphocytes, oxidative stress was induced 
using DEM. Percentage values in this assay were normalized to the untreated control. 
a
 No DEM Treatment. 
b 
DEM Treatment. 
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Table 4 
 
Cytoprotective effects of compounds 12-18 in CEM leukemia cells 
 
______________________________________________________ 
 
Compound                          Cell Viability (%) 
 
______________________________________________________ 
 
                                       0.1 µM               0.5 µM            2.5 µM      
______________________________________________________ 
 
Untreated control
a
         96 ± 1.6             96 ± 1.6            96 ± 1.6    
 
Treated control
b
            7.8 ± 3.2            7.8 ± 3.2           7.8 ± 3.2 
 
12                                 30 ± 4.2              30 ± 5.6            31 ± 1.7 
 
13                                 32 ± 3.3              34 ± 5.9            28 ± 6.3 
 
14                                 19 ± 2.1              18 ± 5.2            31 ± 6.4 
 
15                                 31 ± 2.5              17 ± 5.8            19 ± 2.1        
 
16                                 16 ± 1.0              20 ± 4.0            28 ± 3.4 
 
17                                 17 ± 1.0              14 ± 0.8            18 ± 3.2 
 
18                                 19 ± 6.2              18 ± 4.3            17 ± 3.6 
 
______________________________________________________ 
 
Results for N-hydroxy-4-pyridone derivatives with varying side chains at the C5 position on cell viability are 
as shown. After incubation of test compounds with cultured CEM cells, oxidative stress was induced using 
DEM. Percentage values in this assay were normalized to the untreated control. 
a
 No DEM Treatment. 
b 
DEM Treatment. 
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Table 5 
 
Cytoprotective effects of compounds 19-23 in FRDA lymphocytes 
 
______________________________________________________ 
 
Compound                           Cell Viability (%) 
 
______________________________________________________ 
 
                           0.1 µM        0.5 µM         2.5 µM     
______________________________________________________ 
 
Untreated control
a
         95 ± 3.7      95 ± 3.7        95 ± 3.7 
 
Treated control
b
            11 ± 2.7       11 ± 2.7       11 ± 2.7 
 
19                                  23 ± 3.1      36 ± 2.9        72 ± 4.1 
 
20                                  28 ± 5.0       30 ± 3.2        90 ± 3.3 
 
21                                  42 ± 6.2       73 ± 4.7        92 ± 3.4        
 
22                                  19± 4.1        15± 4.7         19± 8.1 
 
23                                  31 ± 3.9       53 ± 6.5        93 ± 3.7 
 
idebenone                     39 ± 4.3       38 ± 3.6        81 ± 1.9 
 
_____________________________________________________ 
 
Results for pyridinol and pyrimidinols with varying side chains on cell viability are as shown. After incubation 
of test compounds with cultured FRDA lymphocytes, oxidative stress was induced using DEM. Percentage 
values in this assay were normalized to the untreated control. 
a
 No DEM Treatment. 
b 
DEM Treatment. 
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Table 6 
 
Cytoprotective effects of compounds 19-23 in CEM cells 
 
______________________________________________________ 
 
Compound                               Cell Viability (%) 
 
______________________________________________________ 
 
                                 0.1 µM       0.5 µM       2.5 µM      
______________________________________________________ 
 
Untreated control
a
              97 ± 4.9      97 ± 4.9      97 ± 4.9 
 
Treated control
b
                 17 ± 4.9      17 ± 4.9      17 ± 4.9 
 
19                                28 ± 3.1      38 ± 2.4      78 ± 4.8 
 
20                                41 ± 3.7      59 ± 1.4       94 ± 3.4 
 
21                                88 ± 3.1      90 ± 4.6       93 ± 2.4         
 
22                                18 ± 4.6      23 ± 3.6       26 ± 3.5 
 
23                                76 ± 4.9      93 ± 5.1       94 ± 4.1 
 
idebenone                          34 ± 1.9      49 ± 3.2       88 ± 4.3 
 
______________________________________________________ 
 
Results for pyridinol and pyrimidinols with varying side chains on cell viability are as shown. After incubation 
of test compounds with cultured CEM cells, oxidative stress was induced using DEM Percentage values in this 
assay were normalized to the untreated control. 
 
a
 No DEM Treatment. 
 
b 
DEM Treatment. 
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Table 7 
 
 
NADH oxidase activity of compounds 1-5  
______________________________________________________ 
 
Compound               NADH Oxidase Activity (%) 
 
______________________________________________________ 
 
 0.5 µM         1 µM         2.5 µM         5 µM         10µM    
______________________________________________________ 
 
1          94 ± 1.9      92 ± 1.8      83 ± 1.3      80 ± 1.3      74 ± 3.7    
 
2 88 ± 1.5      84 ± 2.7      83 ± 1.7      58 ± 4.3      29 ± 2.7 
    
3 83 ± 2.9      80 ± 1.9      72 ± 5.1      49 ± 4.6      34 ± 4.1 
 
4 96 ± 1.4      80 ± 3.7      73 ± 4.3      72 ± 3.2      58 ± 2.1 
 
5          83 ± 2.1      78 ± 3.7      76 ± 2.1      50 ± 2.1      32 ± 1.1 
 
______________________________________________________ 
 
NADH oxidase activity results for α-tocopherol analogues. Oxidation of NADH was measured 
spectrophotometrically at 340 nm after incubation of SMPs (submitochondrial particle) with synthesized 
compounds. Percentage values in this assay were normalized to the untreated control. 
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 Figure 1: Illustration of potential treatments for FRDA, which are currently supported by FARA (Friedreich’s    
Ataxia Research Alliance). Horizontal axis lists the mechanism of approach. Vertical axis indicate the milestones  
for progress or development.68 
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Figure 2: Compounds 1-5, oxidized analogues of α-tocopherol, were assessed for their cytoprotective effects 
against oxidative stress and inhibition of NADH oxidase. (Synthesis work performed by Dr. David Fash and 
Poulami Talukder) 
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Figure 3: Compounds 6-11 were assessed for their cytoprotective effects against induced oxidative stress. 
(Synthesis work performed by Dr. Xiaoqing Cai) 
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Figure 4: Compounds 12-18, N-hydroxy-4-pyridone compounds, were assessed for their cytoprotective effects 
against induced oxidative stress. (Synthesis work performed by Poulami Talukder) 
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Figure 5: Structures of compounds 19-23 and idebenone. Pyridinol, pyrimidinol and idebenone were assessed 
for their cytoprotective effects against induced oxidative stress. (Synthesis work performed by Pablo Arce) 
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